DK0588917T3 - Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion - Google Patents

Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion

Info

Publication number
DK0588917T3
DK0588917T3 DK92912971T DK92912971T DK0588917T3 DK 0588917 T3 DK0588917 T3 DK 0588917T3 DK 92912971 T DK92912971 T DK 92912971T DK 92912971 T DK92912971 T DK 92912971T DK 0588917 T3 DK0588917 T3 DK 0588917T3
Authority
DK
Denmark
Prior art keywords
isoxazole
cognitive function
enhance cognitive
treatment
isothiazole compounds
Prior art date
Application number
DK92912971T
Other languages
English (en)
Inventor
Youe-Kong Shue
David S Garvey
George M Carrera Jr
Stephen P Arneric
Nan-Horng Lin
Yun He
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0588917T3 publication Critical patent/DK0588917T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92912971T 1991-05-29 1992-05-28 Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion DK0588917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70692091A 1991-05-29 1991-05-29
PCT/US1992/004631 WO1992021339A1 (en) 1991-05-29 1992-05-28 Isoxazole and isothiazole compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
DK0588917T3 true DK0588917T3 (da) 2001-02-12

Family

ID=24839628

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912971T DK0588917T3 (da) 1991-05-29 1992-05-28 Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion

Country Status (13)

Country Link
US (1) US5409946A (da)
EP (1) EP0588917B1 (da)
JP (1) JP3153551B2 (da)
AT (1) ATE197454T1 (da)
BR (1) BR1100981A (da)
CA (1) CA2109585C (da)
DE (1) DE69231557T2 (da)
DK (1) DK0588917T3 (da)
ES (1) ES2153360T3 (da)
GR (1) GR3035285T3 (da)
IE (1) IE921690A1 (da)
PT (1) PT100525B (da)
WO (1) WO1992021339A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678186B2 (en) * 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
US5424444A (en) * 1992-11-25 1995-06-13 Abbott Laboratories Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
WO1996030372A1 (fr) * 1995-03-24 1996-10-03 Japan Tobacco Inc. Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
BR9708815B1 (pt) 1996-04-23 2009-01-13 compostos úteis para prevenção e tratamento de desordens do sistema nervoso central.
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
DK0984943T3 (da) 1997-05-30 2003-03-17 Neurosearch As Azacycloalkan og -alkenderivater, deres fremstilling og anvendelse
ATE231861T1 (de) 1997-05-30 2003-02-15 Neurosearch As 9-azabicyclo(3.3.1)non-2-ene und nonanderivate als liganden der nicotinergen rezeptoren
ATE267199T1 (de) 1997-05-30 2004-06-15 Neurosearch As 8-azabicyclo(3,2,1)oct-2-en- und octanderivate als liganden der nicotinergen ach rezeptoren
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
CN100430066C (zh) * 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
CN100563660C (zh) * 2002-12-20 2009-12-02 麦克莱恩医院 用于正常化睡眠/觉醒周期的化合物
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007533641A (ja) 2003-10-15 2007-11-22 ターガセプト，インコーポレイテッド 疼痛緩和および中枢神経系障害治療のためのアザビシクロ化合物
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
WO2008122049A2 (en) 2007-04-02 2008-10-09 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CA2736871C (en) * 2008-09-11 2019-03-12 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
WO2011085406A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
KR20150119468A (ko) 2013-02-28 2015-10-23 더미라, 인코포레이티드 글리코피롤레이트 염
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Also Published As

Publication number Publication date
IE921690A1 (en) 1992-12-02
EP0588917B1 (en) 2000-11-08
PT100525A (pt) 1993-09-30
JPH06508143A (ja) 1994-09-14
US5409946A (en) 1995-04-25
PT100525B (pt) 1999-10-29
CA2109585C (en) 2000-02-15
ATE197454T1 (de) 2000-11-11
DE69231557T2 (de) 2001-06-21
JP3153551B2 (ja) 2001-04-09
CA2109585A1 (en) 1992-12-10
EP0588917A4 (da) 1994-04-13
GR3035285T3 (en) 2001-04-30
BR1100981A (pt) 2000-04-18
EP0588917A1 (en) 1994-03-30
WO1992021339A1 (en) 1992-12-10
ES2153360T3 (es) 2001-03-01
DE69231557D1 (de) 2000-12-14

Similar Documents

Publication Publication Date Title
DK0588917T3 (da) Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion
DK0663912T3 (da) Heterocykliske etherforbindelser til forstærkning af den kognitive funktion
DE3263734D1 (en) Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (z), their preparation and their use as medicines in the treatment of disorders of the central nervous system
BG102173A (en) Aromatic compounds and pharmaceutical compositions containing them
BR0109703A (pt) Derivados de piperazina
NO960380D0 (no) Middel til behandling av neurosykdommer
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
WO2003031435A8 (en) Pyrazole derivatives as glycine transporter inhibitors
DE69528485D1 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
ZA842185B (en) New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof
HUT66971A (en) 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
PT649846E (pt) Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
MY132077A (en) Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation
CA2450274A1 (en) Benzoxazepine derivatives and their use as ampa receptor stimulators
DK0553778T3 (da) Asymmetrisk hydrogenering
SE8503109D0 (sv) Cyclic prodrugs of antiinflammatory oxicams
GR3020922T3 (en) Amide derivatives of 1-amino-octahydropyrido[2,1-c][1,4]oxazine, processes for their preparation and pharmaceutical compositions containing them
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
ATE181331T1 (de) Salmycine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO943793L (no) Ny anvendelse av
EA200900312A1 (ru) Производные 3,4-дигидробензо[1,2,3]тиадиазин-1,1-диоксида, способ их получения, лекарственные средства, содержащие указанные производные, и их применение
TH18473A (th) การใช้เวนลาแฟกซีนหรือสารประกอบแอริลออกซิ โพรแพแนมีนในการผลิตยาสำหรับการรักษาการกลั้นปัสสาวะไม่อยู่